![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Comprehensive Resistance Testing in Patients Who Relapsed After Treatment With Sofosbuvir (GS-7977)-Containing Regimens in Phase 2 Studies
|
|
|
Reported by Jules Levin
AASLD Nov 9-13 2012 Boston
Evguenia S. Svarovskaia1, Hadas Dvory-Sobol1, Viktoria Gontcharova1, Sophia Chiu1, Christy M. Hebner1, Robert Hyland1, Kris V. Kowdley2, Eric Lawitz3, Edward Gane4, William T. Symonds1, John G. McHutchison1, Michael D. Miller1, Hongmei Mo1
1Gilead Sciences, Inc., Foster City, CA, United States; 2Digestive Disease Institute, Virginia Mason Medical Center, Seattle, WA, United States; 3Alamo Medical Research, San Antonio, TX , United States; 4Auckland City Hospital, Auckland, New Zealand
![AASLD1.gif](../images/111312/111312-3/AASLD1.gif)
![AASLD2.gif](../images/111312/111312-3/AASLD2.gif)
![AASLD3.gif](../images/111312/111312-3/AASLD3.gif)
![AASLD4.gif](../images/111312/111312-3/AASLD4.gif)
![AASLD5.gif](../images/111312/111312-3/AASLD5.gif)
![AASLD6.gif](../images/111312/111312-3/AASLD6.gif)
![AASLD7.gif](../images/111312/111312-3/AASLD7.gif)
![AASLD8.gif](../images/111312/111312-3/AASLD8.gif)
![AASLD9.gif](../images/111312/111312-3/AASLD9.gif)
![AASLD10.gif](../images/111312/111312-3/AASLD10.gif)
![AASLD11.gif](../images/111312/111312-3/AASLD11.gif)
![AASLD12.gif](../images/111312/111312-3/AASLD12.gif)
![AASLD13.gif](../images/111312/111312-3/AASLD13.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|